Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00260832 · ClinicalTrials.gov registry record · Phase 3
Trial of Decitabine in Patients With Acute Myeloid Leukemia
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 485
- Enrollment target
NCT00260832 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 485 participants.
The verdict
NCT00260832, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 485 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the results in older patients who have newly diagnosed or secondary acute myeloid leukemia (AML) and who are to either receive decitabine or patient's choice with the physician's advice of either cytarabine or supportive care medication.
Interventions
- DRUG Cytarabine or Supportive Care
- DRUG Dacogen (decitabine) only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00260832
The ClinicalTrials.gov registry entry for NCT00260832 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 485 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine or Supportive Care is the first listed.
NCT00260832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00260832 about?
NCT00260832 is a clinical study titled "Trial of Decitabine in Patients With Acute Myeloid Leukemia". The purpose of this study is to compare the results in older patients who have newly diagnosed or secondary acute myeloid leukemia (AML) and who are to either receive decitabine or patient's choice with the physician's advice of either cytarabine or supportive care medication.
What is the current status of trial NCT00260832?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 485 participants. The study started on 2005-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00260832?
The interventions under investigation include: Cytarabine or Supportive Care (DRUG), Dacogen (decitabine) only (DRUG).
Who is sponsoring clinical trial NCT00260832?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.